| 翻訳と辞書 |
rituximab
Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system. It has a wholesale price of between 159.00 and 2,480.00 USD per vial as of 2014.〔(【引用サイトリンク】url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RITX10I&s_year=2014&year=2014&str=10%20mg%2Fml&desc=Rituximab&pack=new&frm=AMPOULE&rte=INJ&class_code2=08%2E2%2E&supplement=&class_name=%2808%2E2%2E%29Cytotoxic%20and%20adjuvant%20medicines%3Cbr%3E )〕
== Medical uses ==
Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells, or dysfunctional B cells.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「rituximab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|